Protagonist Therapeutics (PTGX) Receivables - Other (2017 - 2026)

Protagonist Therapeutics (PTGX) has 10 years of Receivables - Other data on file, last reported at $3.5 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables - Other fell 84.85% year-over-year to $3.5 million; the trailing twelve-month figure through Mar 2026 stood at $3.5 million (down 84.85% YoY), and the FY2025 full-year result was $4.4 million, up 34.64% from the prior year.
• Receivables - Other fell to $3.5 million in Q1 2026, from $4.4 million in the prior quarter.
• In the past five years, Receivables - Other ranged from a high of $23.4 million in Q2 2025 to a low of $39000.0 in Q2 2023.
• A 5-year average of $4.9 million and a median of $672000.0 in 2022 frame the typical range for Receivables - Other.
• Across the five-year window, Receivables - Other slumped 97.32% in 2022 and surged 1166.41% in 2024, its largest moves.
• Tracing PTGX's Receivables - Other over 5 years: stood at $42000.0 in 2022, then jumped by 509.52% to $256000.0 in 2023, then surged by 1166.41% to $3.2 million in 2024, then soared by 34.64% to $4.4 million in 2025, then fell by 20.76% to $3.5 million in 2026.
• Business Quant data shows PTGX's Receivables - Other at $3.5 million in Q1 2026, $4.4 million in Q4 2025, and $4.6 million in Q3 2025.